MeiraGTx Holdings (MGTX) Non-Current Debt (2021 - 2026)
MeiraGTx Holdings' (MGTX) quarterly Non-Current Debt came in at $49.7 million in Q4 2025, down 32.14% YoY from $73.2 million in Q4 2024, and down 32.65% on a QoQ basis from $73.8 million in Q2 2025.
Analysis
MeiraGTx Holdings (MGTX) Non-Current Debt (2021 - 2026) Analysis & Trends
MeiraGTx Holdings (MGTX) has 5 years of Non-Current Debt data on file, last reported at $49.7 million in Q4 2025.
- Quarterly Non-Current Debt fell 32.14% year-over-year to $49.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $49.7 million (down 32.14% YoY) and the FY2025 annual result came in at $49.7 million, down 32.14% from the prior year.
- Non-Current Debt slipped to $49.7 million in Q4 2025, from $73.8 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $73.8 million in Q2 2025 to a low of $208000.0 in Q1 2023.
- A 5-year average of $48.6 million and a median of $71.7 million in 2023 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2022 — Non-Current Debt slumped 72.51% — and 2024, when it surged 34703.37%.
- Tracing MGTX's Non-Current Debt over 5 years: stood at $953000.0 in 2021, then tumbled by 72.51% to $262000.0 in 2022, then jumped by 27426.34% to $72.1 million in 2023, then grew by 1.53% to $73.2 million in 2024, then plunged by 32.14% to $49.7 million in 2025.
- The last three Non-Current Debt figures came in at $49.7 million (Q4 2025), $73.8 million (Q2 2025), and $73.5 million (Q1 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 591.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 882.16 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 8.96 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 546.77 Mn |
| 10 | MeiraGTx Holdings | 1.27 Bn | 1.13 Bn | 315.67 Mn | 100.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 100.00 Mn |
| Dec 31, 2025 | 49.69 Mn |
| Jun 30, 2025 | 73.77 Mn |
| Mar 31, 2025 | 73.50 Mn |
| Dec 31, 2024 | 73.22 Mn |
| Sep 30, 2024 | 72.94 Mn |
| Jun 30, 2024 | 72.67 Mn |
| Mar 31, 2024 | 72.39 Mn |
| Dec 31, 2023 | 72.12 Mn |
| Sep 30, 2023 | 71.84 Mn |
| Jun 30, 2023 | 71.57 Mn |
| Mar 31, 2023 | 71.30 Mn |
| Dec 31, 2022 | 71.03 Mn |
| Sep 30, 2022 | 70.85 Mn |
| Jun 30, 2022 | 304,000.00 |
| Mar 31, 2022 | 556,000.00 |
| Dec 31, 2021 | 953,000.00 |